PER-015-18尚未招募未知
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PIMODIVIR IN COMBINATION WITH THE STANDARD-OF-CARE TREATMENT IN ADOLESCENT, ADULT, AND ELDERLY NON-HOSPITALIZED SUBJECTS WITH INFLUENZA A INFECTION WHO ARE AT RISK OF DEVELOPING COMPLICATIONS.
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male or female, 13 to 85 years of age, inclusive. Note: Adolescent subjects (13-17 years) will be enrolled in selected countries and study sites consistent with local regulations.
- •Present to the clinic with symptoms suggestive of a diagnosis of acute influenza and have at least 1 respiratory symptom and at least 1 systemic symptom, both scored as at least moderate” if the symptom did not pre-exist before influenza onset, or scored worse than usual if the symptom pre-existed. Symptoms must include the following by category: respiratory symptoms: cough, sore throat, nasal congestion; systemic symptoms: headache, body aches or pain, feverishness, fatigue.
- •Tested positive for influenza A infection after the onset of symptoms, using a rapid influenza diagnostic test (RIDT) or, if available, a PCR-based molecular diagnostic assay.
- •Not be in need of hospitalized medical care at screening. Emergency room or hospital observation status for <24 hours is not considered hospitalization as long as a determination of the need for hospitalization has not been made.
- •Enrollment and initiation of study drug treatment ≤72 hours after onset of influenza symptoms.
- •Subjects 13 to 65 years of age, inclusive must also have at least one of the following:
- •Cardiovascular or cerebrovascular disease (including congenital heart disease, chronic heart failure, coronary artery disease, or stroke).
- •Chronic lung disease (eg, asthma, chronic obstructive lung disease [COPD] or cystic fibrosis).
- •Weakened immune system due to disease or medication (eg, subjects with human immunodeficiency virus [HIV], cancer, or chronic liver or kidney disease, or subjects taking chronic systemic steroids).
排除标准
- •Received more than 1 dose of influenza antiviral medication (eg, oseltamivir [OST] or zanamivir), or any dose of ribavirin within 2 weeks, prior to first study drug intake, or received intravenous (IV) peramivir more than 1 day prior to screening.
- •Unwilling to undergo regular nasal mid-turbinate (MT) swabs or has any physical abnormality which limits the ability to collect regular nasal MT specimens.
- •Unstable angina pectoris or myocardial infarction within 30 days prior to screening (inclusive).
- •Presence of clinically significant heart arrhythmias, uncontrolled, unstable atrial arrhythmia, or sustained ventricular arrhythmia, or risk factors for Torsade de Pointes syndrome.
- •Chronic hepatitis C infection undergoing antiviral therapy.
- •Severely immunocompromised in the opinion of the investigator (eg, cluster of differentiation 4+ [CD4+] count <200 cells/mm3, absolute neutrophil count <750/mm3, first course of chemotherapy completed within 2 weeks prior to screening, history of stem cell transplant within 1 year prior to screening, history of a lung transplant).
研究者
相似试验
已完成
不适用
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUPSTUDY TO EVALUATE THE SAFETY AND EFFICACY OF DENOSUMAB IN PEDIATRIC SUBJECTSWITH GLUCOCORTICOID-INDUCED OSTEOPOROSIS.-M804M804PER-022-18AMGEN INC.,1
进行中（未招募）
不适用
CLINICAL TRIAL OF THE SAFETY AND EFFECTIVENESS OF IMMUNE GLOBULIN INTRAVENOUS (HUMAN), 10% SOLUTION (IGIV, 10%) FOR THE TREATMENT OF MILD TO MODERATE ALZHEIMER’S DISEASE (AD)Mild to moderate Alzheimer’s disease (AD)MedDRA version: 15.0Level: HLTClassification code 10001897Term: Alzheimer's disease (incl subtypes)System Organ Class: 10029205 - Nervous system disordersEUCTR2011-000914-21-PLBaxter Innovations GmbH402
进行中（未招募）
1 期
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEEOsteoarthritis of the hip or kneeMedDRA version: 21.1Level: LLTClassification code 10020108Term: Hips osteoarthritisSystem Organ Class: 100000004859MedDRA version: 21.1Level: LLTClassification code 10023476Term: Knee osteoarthritisSystem Organ Class: 100000004859EUCTR2013-004508-21-ITPFIZER INC849
进行中（未招募）
1 期
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB (PF-04383119) IN SUBJECTS WITH CANCER PAIN PREDOMINANTLY DUE TO BONE METASTASIS RECEIVING BACKGROUND OPIOID THERAPYMetastatic Bone PainMedDRA version: 20.0Level: LLTClassification code 10049038Term: Metastatic bone painSystem Organ Class: 100000004864EUCTR2013-002223-42-GBPfizer Inc,155
招募中
不适用
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PEMBROLIZUMAB (MK-3475) PLUS CHEMOTHERAPY VERSUS CHEMOTHERAPY PLUS PLACEBO FOR THE FIRST-LINE TREATMENT OF PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER (KEYNOTE-826)-C53 Malignant neoplasm of cervix uteriMalignant neoplasm of cervix uteriC53PER-038-18Merck Sharp & Dohme Corp., una subsidiaria de Mer·ck & Co. Inc.,7